Quantum Partners exclusively advised Goodly Innovations GmbH and its shareholders in the M&A process
acquires
Andreas Brinkrolf has many years of corporate finance experience and has already founded several successful companies.
As Venture Manager and later as Managing Director of the Siemens Technology Accelerator, he was responsible for the external marketing of Siemens technologies through sales, spin-offs and licensing. The focus was on high-tech projects, e.g. in the fields of sensor technology, new materials and software.
As founder and CEO of Tiburon Partners AG, he invested in Internet and software companies and accompanied some of the companies through their entire life cycle to exit. He was responsible for the subsequent sale of Tiburon Partners AG to a listed holding company. Mr. Brinkrolf was a co-founder of Invoco Holding GmbH and helped it develop into one of the leading providers of outsourcing services in Germany. In 2013, he was responsible for the sale of the company to Xerox Corporation. In recent years, Mr. Brinkrolf has advised on over 50 transactions - initial investments, capital increases and sales.
He studied business administration at the Universities of Bamberg and Aston (UK) and completed his doctorate at the University of St. Gallen (CH).
Andreas Brinkrolf
Deal Partner
brinkrolf@quantum-partners.de
+49 89 414 144 355
Quantum Partners advises Goodly Innovations GmbH and its shareholders on the sale to BioNTech SE
Compared to other industries, the biotech and pharmaceutical sector has not yet been able to keep pace with the introduction of Industry 4.0 practices. Today, the ongoing shortage of skilled workers as well as strong cost and innovation pressures are pushing process optimization and productivity to the forefront. According to a report by Bain & Company, Industry 4.0 practices in the pharmaceutical segment have the potential to reduce manufacturing costs by up to 20% while improving product quality.
There is considerable potential for optimization in the manufacture and packaging of pharmaceutical products. A large proportion of work processes in production and laboratories are still based on paper-based documentation. The average effective operating time of pharmaceutical production machines is only around 35%. In addition, it takes more than three months on average to train new employees. Complex manual processes for operating the machines lead to a high susceptibility to errors.
With “OptiworX”, Goodly Innovations GmbH offers a state-of-the-art software solution that takes process management and quality in the biotech and pharmaceutical industry to a new level. OptiworX supports manual processes through augmented reality (AR) guidance. This transformative technology minimizes human error, ensures regulatory compliance to GMP standards and significantly improves operational safety. The use of OptiworX generates high added value for customers: increasing machine productivity by up to 50%, training new employees up to 90% faster and avoiding human error during machine changeovers.
The strategic acquirer of Goodly Innovations technology is a German-based biotechnology company that is integrating the OptiworX solution into its existing MES solution in order to optimize process control in development and production, among other things.
About Goodly Innovations
Goodly Innovations GmbH is a provider of highly innovative process guidance technology based in Munich. The OptiworX software offered is the leading solution for optimizing complex manual processes through augmented reality guidance (“Operator AR Guidance”)
About Quantum Partners
Quantum Partners GmbH, headquartered in Munich, is a specialized corporate finance advisor that supports clients in company transactions as well as in finding financing.
